Roche is looking to offload its idiopathic pulmonary fibrosis drug Esbriet as more patients with the fatal lung disease opt for generic versions and Big Pharmas continue to shed non-core assets.
Aug 1 (Reuters) - Swiss drugmaker Roche's Genentech [RIC:RIC:ROGING.UL] subsidiary has accused a Novartis (NOVN.S) unit of infringing one of its patents by selling a generic version of its blockbuster lung disease drug Esbriet, after an earlier lawsuit failed to keep the generic drug off the market.
Apotex's Generic Pirfenidone Receives Approval in the U.S.
Enforcement Report - Week of March 8, 2023
Viatris`s Pirfenidone Viatris (pirfenidone) Receives Approval in Europe
Hetero's Generic Pirfenidone Receives Approval in the U.S.
ScieGen Pharma's Generic Pirfenidone Receives Approval in the U.S.
Aizant Generic Pirfenidone Receives Approval in the U.S.
Laurus Labs Generic Pirfenidone Receives Approval in the U.S.